ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $232,383 | -32.6% | 43,763 | +20.9% | 0.00% | – |
Q2 2023 | $344,964 | +84.1% | 36,184 | +112.4% | 0.00% | – |
Q1 2023 | $187,396 | -20.5% | 17,036 | +6.9% | 0.00% | – |
Q4 2022 | $235,852 | -19.0% | 15,936 | +4.8% | 0.00% | – |
Q3 2022 | $291,000 | +15.5% | 15,213 | +28.9% | 0.00% | – |
Q2 2022 | $252,000 | +50.0% | 11,804 | +35.2% | 0.00% | – |
Q1 2022 | $168,000 | -7.2% | 8,732 | 0.0% | 0.00% | – |
Q4 2021 | $181,000 | -13.4% | 8,732 | 0.0% | 0.00% | – |
Q3 2021 | $209,000 | +102.9% | 8,732 | +130.8% | 0.00% | – |
Q2 2021 | $103,000 | -17.6% | 3,783 | -12.7% | 0.00% | – |
Q1 2021 | $125,000 | +83.8% | 4,333 | +79.5% | 0.00% | – |
Q4 2020 | $68,000 | +7.9% | 2,414 | +11.9% | 0.00% | – |
Q3 2020 | $63,000 | +31.2% | 2,157 | +37.3% | 0.00% | – |
Q2 2020 | $48,000 | 0.0% | 1,571 | -2.8% | 0.00% | – |
Q1 2020 | $48,000 | – | 1,617 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
Two Seas Capital LP | 164,807 | $875,125 | 0.18% |